“From left to right we have Hilary Reynolds, Professor Dame Caroline Watkins, Cathy Rice, Dr Lisa Hinton, and Laura Piercy. This means that it can be used in different settings, for example, it could potentially be given in ambulances on the way to hospital. “The drug can be … However, researchers at the University of Manchester have previously shown that IL-1 increases inflammation and brain injury following a stroke. She also subsequently worked on the North West London Integrated Care Programme and has co-ordinated a number of successful integration projects and initiatives. Stroke is the leading cause of mortality and disability in China and the second leading cause of death in the world. Read the findings from the UK Health Research Analysis 2018, and find out more about our research.
. The protein Interleukin-1 (IL-1) is part of the body's defences and naturally produced to combat a range of illnesses. After graduating from Cambridge University, he joined Donaldson, Lufkin and Jenrette (later Credit Suisse First Boston) as a Mergers and Acquisitions analyst, followed by a move to UBS Wealth Management and Europe Arab Bank where he headed the Structured Products department. He was a senior audit partner of Ernst and Young with senior client service roles with a wide variety of listed companies, large private companies and universities. AMRC is a registered charity in England and Wales (296772). The charity’s work to fund pioneering research, campaign for better stroke care, and push for greater awareness of stroke has never been more crucial. Hilary Reynolds CBE, Executive Director for Strategy and Research, The Stroke Association. An anti-inflammatory drug given to patients in the early stages of a stroke has been shown by researchers at The University of Manchester and Salford Royal NHS Foundation Trust to reduce harmful inflammation. Hilary comes to the charity sector after 30 years in public service, working for central government here and in New Zealand in the social … 3 Current data show that homocysteine is an important risk factor of stroke, 4 especially in hypertensive patients. Andrew joined us in July 2017 and oversees all our fundraising and commercial activity. We support them in saving and improving lives through research and innovation. See the complete profile on LinkedIn and discover Hilary’s connections and jobs at similar companies. Their study, funded by the Stroke Association, follows earlier research that shows the drug given as an intravenous therapy reduces inflammation in stroke and sub arachnoid haemorrhage patients. There are two main types of stroke: ischemic, caused by lack of blood flow, and haemorrhagic, caused by bleeding in the brain. Join us and become part of a network of 150 medical and health research charities who deliver high-quality research that saves and improves lives, Negotiations continue to determine the UK’s new relationship with the EU. The UK Health Research Analysis 2018 also shows stroke research receives much less funding than many other areas of health research. We are a membership organisation for over 140 medical research charities across the UK. Group Chief Information Officer, Tri-Borough. Chris joined the Stroke Association in September 2019 and is responsible for overseeing all aspects of the charity’s financial management and procurement. The current study, which was a double-blind trial where anakinra was tested against placebo at the trust’s stroke centre at the Salford Royal Hospital, looked at ischemic strokes only. Hilary Reynolds, Executive Director of Research at the Stroke Association said: She was awarded a CBE in the 2018 New Year Honours for services to policy and research. “The research has not yet proven that this drug can reduce patient disability after stroke. After completing a short period in the nursing profession, Chris spent his early management career with an international charity in the area of community service management and delivery. Quotes from our people. There are currently 16 Trustees, led by our Chair, Stephen King: Stephen is a long-serving trustee of the charity Sightsavers International and is deputy chair of NHS West Essex. Hilary Reynolds, executive director of strategy and research at the Stroke Association, said: “This study builds on evidence that Kineret helps to reduce inflammation and brain damage in a wide range of stroke patients soon after a stroke.